DUPIXENT

Generic: DUPILUMAB

Manufacturer: Sanofi-Aventis U.S. Llc

Interleukin-4 Receptor alpha Antagonist [EPC]Corticosteroid [EPC]Nonsteroidal Anti-inflammatory Drug [EPC]Provitamin D2 Compound [EPC]Proton Pump Inhibitor [EPC]
411,692
Total Reports
344,853
Serious Reports
1,769
Death Reports
30
Reported Reactions
Death Report Ratio: Low (0.43%)

Patient Demographics

Male
151,443
Female
236,958

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for DUPIXENT.

# Reaction Reports % of Total
1 PRURITUS 48,441
9.4%
2 DERMATITIS ATOPIC 37,675
7.3%
3 PRODUCT USE IN UNAPPROVED INDICATION 36,010
7.0%
4 RASH 33,431
6.5%
5 INJECTION SITE PAIN 30,477
5.9%
6 DRUG INEFFECTIVE 26,034
5.0%
7 ECZEMA 22,304
4.3%
8 DRY SKIN 21,662
4.2%
9 PRODUCT DOSE OMISSION ISSUE 20,789
4.0%
10 CONDITION AGGRAVATED 18,451
3.6%
11 ARTHRALGIA 16,570
3.2%
12 INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 16,307
3.2%
13 ASTHMA 13,665
2.6%
14 SKIN EXFOLIATION 12,486
2.4%
15 ACCIDENTAL EXPOSURE TO PRODUCT 12,191
2.4%
16 ERYTHEMA 11,817
2.3%
17 OFF LABEL USE 11,762
2.3%
18 DRY EYE 11,640
2.3%
19 DYSPNOEA 11,604
2.2%
20 INCORRECT DOSE ADMINISTERED 10,859
2.1%
21 PRODUCT USE ISSUE 10,632
2.1%
22 INJECTION SITE SWELLING 10,336
2.0%
23 EXPOSURE VIA SKIN CONTACT 10,321
2.0%
24 INJECTION SITE ERYTHEMA 9,484
1.8%
25 COUGH 9,331
1.8%
26 EYE PRURITUS 8,919
1.7%
27 PRODUCT DOSE OMISSION IN ERROR 8,398
1.6%
28 THERAPEUTIC RESPONSE DECREASED 8,289
1.6%
29 PAIN 8,130
1.6%
30 HEADACHE 7,983
1.5%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.